Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg nudges up target price on Shaftesbury Capital

(Sharecast News) - Analysts at Berenberg hiked their target price on real estate investment trust Shaftesbury Capital from 160.0p to 174.0p on Friday, citing a broad-based recovery. Berenberg said Shaftesbury Capital's interim results on 31 July suggested early signs of growth across most of its sub-sectors and locations within its portfolio, with only residential reporting a decline in values of 1%.

The German bank stated this reflected Shaftesbury's "unique Central London offering", as well as increasing demand for not only its retail and hospitality space but also for its office product.

"Shaftesbury Capital was one of our top-picks for the start of the year, and while the shares are up 6% year-to-date, outperforming the wider UK REIT sector, they still trade at a relatively wide 24% to the reported net tangible assets," said Berenberg, which reiterated its 'buy' rating on the stock.

"We have revised our forecasts, edging back our earnings per share estimates to 4.0p (was 4.2p) for FY24E, 4.5p (was 4.7p) for FY25E and 4.7p (was 4.9p) for FY26E. This has a knock-on impact on our dividend estimates given that we broadly assume a 90% payout ratio. Our NTA estimates are, however, unchanged."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.